Get the Stockscreener App
18.35
2.97%
0.53
After Hours:
18.20
-0.15
-0.82%
Arcturus Therapeutics Holdings Inc stock is traded at $18.35, with a volume of 328.88K.
It is up +2.97% in the last 24 hours and down -23.16% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
See More
Previous Close:
$17.82
Open:
$17.71
24h Volume:
328.88K
Relative Volume:
0.94
Market Cap:
$496.23M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
6.1371
EPS:
2.99
Net Cash Flow:
$-21.00M
1W Performance:
-4.03%
1M Performance:
-23.16%
6M Performance:
-32.71%
1Y Performance:
-6.28%
1-Day Range:
$17.26
$18.40
1-Week Range:
$17.26
$19.01
52-Week Range:
$17.26
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect - Yahoo Finance
Empire Life Investments Inc. Makes New $3.50 Million Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (ARCT) Scheduled to Post Earnings on Thursday - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 - Business Wire
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Arcturus falls after detailed Phase 1 data for cystic fibrosis therapy - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 6.1%What's Next? - MarketBeat
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain - Yahoo Finance
8,235 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Acquired by SG Americas Securities LLC - Defense World
A slow start for self-amplifying mRNA vaccines - Yahoo Finance
Vontobel Holding Ltd. Trims Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.8% Following Insider Selling - MarketBeat
AQR Capital Management LLC Has $285,000 Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Insider Sale at Arcturus Therapeutics Holdings Inc (ARCT) - GuruFocus.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 Shares - MarketBeat
Arcturus Therapeutics executive sells $249,121 in stock By Investing.com - Investing.com Canada
Arcturus Therapeutics executive sells $249,121 in stock - Investing.com India
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Update - MarketBeat
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way - GlobeNewswire Inc.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Price Target from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Consensus Price Target from Analysts - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.9%Time to Sell? - MarketBeat
Squarepoint Ops LLC Takes Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Marshall Wace LLP Cuts Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.4% – Here’s Why - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.4%Time to Sell? - MarketBeat
Point72 Asia Singapore Pte. Ltd. Makes New Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
ARCTURUS THERAPEUTICS HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified - Simply Wall St
Dimensional Fund Advisors LP Sells 185,598 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Leerink Partners’s latest rating for ARCT stock - Knox Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Unveiling 3 Analyst Insights On Arcturus Therapeutics - Benzinga
Arcturus Therapeutics' (ARCT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses - Yahoo Finance
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - Lelezard
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination – Company AnnouncementFT.com - Financial Times
Here's Why Investors Should Invest in Arcturus Stock Now - MSN
American Century Companies Inc. Has $2.49 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Wall Street SWOT: Arcturus Therapeutics stock rides wave of vaccine innovation - Investing.com
Deerfield Management Company L.P. Series C Takes $958,000 Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences - Yahoo Finance
XTX Topco Ltd Invests $596,000 in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Trading 4.3% Higher - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.5% - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.5% - Defense World
Cystic Fibrosis (CF) Therapeutics Market Report 2024: Global Size, Share, Growth, Trends, Forecast To 2033 - WhaTech
Quest Partners LLC Raises Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Trading Up 6.6% - MarketBeat
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):